Founded in 2018, Neurogene is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. The company focuses on gene therapy approaches to address conditions with limited treatment options, leveraging adeno-associated virus and conventional gene therapy technologies.
The company's pipeline includes NGN-401, a Phase 1/2 candidate for Rett syndrome, and NGN-101, also in Phase 1/2 development for CLN5 Batten disease. Both candidates represent early-stage programs with development partnerships established through license agreements with academic institutions including The University of Edinburgh and Stanford University, as well as commercial collaborators.
Neurogene operates as a private development-stage company with 107 full-time employees, headquartered in New York. The company has not yet generated material product revenues and remains dependent on funding to support clinical development activities.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-4.28 | $-4.28 | -246.1% | |
| 2023 | $2.93 | $27.76 | +381.7% | |
| 2022 | $-1.04 | $-1.04 | +5.5% | |
| 2021 | $-1.10 | $-1.10 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-24 | 0001404644-25-000012 | SEC ↗ |
| 2023-12-31 | 2024-03-18 | 0001404644-24-000020 | SEC ↗ |
| 2022-12-31 | 2023-03-20 | 0001628280-23-008602 | SEC ↗ |
| 2021-12-31 | 2022-03-01 | 0001628280-22-004491 | SEC ↗ |
| 2020-12-31 | 2021-03-25 | 0001628280-21-005630 | SEC ↗ |
| 2019-12-31 | 2020-03-12 | 0001193125-20-071545 | SEC ↗ |
| 2018-12-31 | 2019-03-07 | 0001193125-19-066506 | SEC ↗ |
| 2017-12-31 | 2018-03-12 | 0001193125-18-079210 | SEC ↗ |
| 2016-12-31 | 2017-03-09 | 0001193125-17-076939 | SEC ↗ |
| 2015-12-31 | 2016-03-14 | 0001193125-16-503435 | SEC ↗ |
| 2014-12-31 | 2015-03-16 | 0001193125-15-093873 | SEC ↗ |